

## Annual General Meeting Date

---

**Melbourne, Australia, 24 September 2024:** In accordance with ASX Listing Rule 3.13.1, 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) advises that its next Annual General Meeting (“AGM”) will be held at 10.00 am on Wednesday, 20 November 2024. An election of directors will be held at this AGM pursuant to ASX Listing Rule 14.5. Details of the Directors to be elected will be included in the forthcoming Notice of AGM.

The Closing Date for receipt of nominations for the position of Director is 2 October 2024. Any nominations must be received in writing by no later than 5.00pm AEST on this date at the Company’s Registered Office.

–ENDS–

Authorised by the 4DMedical Board of Directors.

### Contacts

#### Corporate

Chief Financial Officer  
Simon Glover  
[sglover@4dmedical.com](mailto:sglover@4dmedical.com)

#### Administration

Company Secretary  
Naomi Lawrie  
[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

#### Media Enquiries

[4Dmedia@4dmedical.com](mailto:4Dmedia@4dmedical.com)

### About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) – the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS™.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio’s regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalised care for patients.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com)

#### Melbourne

Level 7 Melbourne Connect  
700 Swanston Street  
Carlton VIC 3053  
Tel: +61 (3) 9545 5940

#### Los Angeles

21255 Burbank Boulevard  
Suite 120  
Woodland Hills CA 91367  
Tel: +1 (818) 403-8490

4DMedical Limited  
ABN: 31 161 684 831  
Email: [info@4DMedical.com](mailto:info@4DMedical.com)  
[www.4DMedical.com](http://www.4DMedical.com)